` CU6 (Clarity Pharmaceuticals Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

C
CU6
vs
S
S&P/ASX 300

Over the past 12 months, CU6 has underperformed S&P/ASX 300, delivering a return of -17% compared to the S&P/ASX 300's +4% growth.

Stocks Performance
CU6 vs S&P/ASX 300

Loading
CU6
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CU6 vs S&P/ASX 300

Performance Gap Between CU6 and AXKO
HIDDEN
Show

Performance By Year
CU6 vs S&P/ASX 300

Loading
CU6
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Clarity Pharmaceuticals Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Clarity Pharmaceuticals Ltd
Glance View

Market Cap
1.1B AUD
Industry
Pharmaceuticals

Clarity Pharmaceuticals Ltd. engages in the development of radiopharmaceutical products focused on the treatment of serious diseases. The firm is focused on developing products to address the growing need for radiopharmaceuticals in oncology. Its has a diverse range of products in clinical trials which address both large indications such as prostate cancer and breast cancer, as well as rare and orphan indications such as neuroendocrine tumours (NETs) and neuroblastoma of cancer. The SAR Technology platform is the Company’s platform. Its pipeline of products in clinical and preclinical stages include SARTATE, SAR-Bombesin and SAR-bisPSMA. Its SARTATE is for the treatment of neuroblastoma, and for the diagnosis of NETs. Its SAR-Bombesin is a pan-cancer treatment product, including for the treatment of breast cancer and prostate cancer. Its SAR-bisPSMA is for the treatment of prostate cancer, and for the diagnosis of prostate cancer.

CU6 Intrinsic Value
HIDDEN
Show
Back to Top